CBR1 Polyclonal Antibody, Cy3 Conjugated

• Background:

  NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.

• Synonyms:

  Carbonyl reductase [NADPH] 1; CBR1; 15-hydroxyprostaglandin dehydrogenase [NADP (+) ]; NADPH-dependent carbonyl reductase 1; Prostaglandin 9-ketoreductase; Prostaglandin-E (2) 9-reductase (EC:1.1.1.189) ; Short chain dehydrogenase/reductase family 21C member 1; CBR; CRN; SDR21C1

• Gene ID:

  873

• Swiss Prot:

  P16152

• Cellular Locus:

  Cytoplasm

• Host:

  Rabbit

• Cross Reactivity:

  Mouse

• Immunogen:

  201-277/277

• Target:

  CBR1

• Clonality:

  Polyclonal

• Isotype:

  IgG

• Conjugation:

  Cy3

• Source:

  KLH conjugated synthetic peptide derived from human CBR1

• Applications:

  WB, IF (IHC-P), IF (IHC-F), IF (ICC)

• Purification:

  Purified by Protein A.

• Excitation Emission:

  512,550nm/570,615nm

• Concentration:

  1µg/µl

• Dilution:

  WB (1:300-5000), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

• Buffer:

  Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

• Modification:

  Unmodified

• Storage Conditions:

  Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

• Gene ID URL:

  873

• Predicted Cross Reactivity:

  Human, Rat